Related Experiment Videos
Duloxetine: a dual reuptake inhibitor
Sara E Dugan1, Matthew A Fuller
1Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10000 Brecksville Rd., Brecksville, OH 44141, USA.
The Annals of Pharmacotherapy
|November 4, 2004
Summary
Duloxetine, a serotonin-norepinephrine reuptake inhibitor, is an effective and safe treatment for major depressive disorder (MDD). This medication offers a new option for managing MDD symptoms with generally mild side effects.
Area of Science:
- Pharmacology and Psychiatry
Background:
- Major Depressive Disorder (MDD) is a prevalent mental health condition.
- Pharmacological interventions are crucial for managing MDD.
- Duloxetine is a novel antidepressant agent.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of duloxetine for MDD treatment.
- To assess duloxetine's potential as a therapeutic option for major depressive disorder.
Main Methods:
- Comprehensive literature search of MEDLINE and PsycINFO databases (1966-2003).
- Evaluation of articles with detailed information on duloxetine for MDD.
Main Results:
- Duloxetine, a serotonin-norepinephrine reuptake inhibitor, demonstrates efficacy and safety in treating acute MDD.
- Recommended dosing is 40-60 mg twice daily.
- Adverse effects are typically mild, transient, and well-tolerated.
- Observed cardiovascular effects are not clinically significant.
Conclusions:
- Duloxetine is confirmed as a safe and effective antidepressant.
- Its approval provides an additional valuable treatment option for major depressive disorder management.